(Q36238352)
Statements
1 reference
Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy ( (English)
1 reference
A T Fung
1 reference
N Kumar
1 reference
S K Vance
1 reference
J S Slakter
1 reference
J M Klancnik
1 reference
R S Spaide
1 reference
K B Freund
1 reference
Identifiers
1 reference